CoChat
Sign Up
Cited by 55Gastrointestinal motility and disordersGut microbiota and healthProbiotics and Fermented Foods

Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone

Kang, Dae-Wook, DiBaise, John K., Ilhan, Zehra Esra, Crowell, Michael D., Rideout, Jai Ram, Caporaso, J. Gregory, Rittmann, Bruce E., Krajmalnik-Brown, Rosa·2015·Anaerobe
DOI 10.1016/j.anaerobe.2015.01.005
Open this paper in CoChat — free account

Abstract

Identifying specific gut microorganisms associated with chronic constipation may be useful for diagnostic and therapeutic purposes. The objective of this study was to evaluate whether or not the gut microbial community of constipated subjects had specific microbial signatures and to assess the effects of lubiprostone treatment on the gut microbial community. Stool diaries, breath H2 and CH4 levels, and stool samples were collected from ten healthy subjects and nine patients meeting the Rome III criteria for chronic functional constipation. Constipated subjects received lubiprostone for four weeks, during which stool diaries were maintained. Stool samples were evaluated for gut microbial communities using pyrosequencing and quantitative real-time PCR (qPCR) targeting 16S-rRNA gene, along with concentrations of short-chain fatty acids (SCFAs) using high-performance liquid chromatography. Prior to treatment, gut microbial profiles were similar between constipated subjects and healthy subjects, while iso-butyrate levels were significantly higher in constipated subjects compared with healthy subjects. Despite increases in stool frequency and improvements in consistency after lubiprostone treatment, gut microbial profiles and community diversity after treatment showed no significant change compared to before treatment. While we did not observe a significant difference in either breath methane or archaeal abundance between the stool samples of healthy and constipated subjects, we confirmed a strong correlation between archaeal abundance measured by qPCR and the amount of methane gas exhaled in the fasting breath. Butyrate levels, however, were significantly higher in the stool samples of constipated subjects after lubiprostone treatment, suggesting that lubiprostone treatment had an effect on the net accumulation of SCFAs in the gut. In conclusion, lubiprostone treatment improved constipation symptoms and increased levels of butyrate without substantial modification of the gut microbial structure.

Integrity signals

Registry

Crossref · 10.1016/j.anaerobe.2015.01.005

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elevated levels of short-chain fatty acids are found in the stools of functional constipation patients.

    “Elevated levels of SCFAs are found in the stools of FC patients.”

    From Role of gut microbiota in functional constipation (2021) · cites this paper as [55]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Kang, D.-W., DiBaise, J. K., Ilhan, Z. E., Crowell, M. D., Rideout, J. R., Caporaso, J. G., Rittmann, B. E., & Krajmalnik-Brown, R.
Affiliations
  • Arizona State University (US)
  • Mayo Clinic (US)
  • Northern Arizona University (US)
Corresponding author
DiBaise, John K.
ORCID
Venue
Anaerobe
Publisher
Elsevier BV
Published
2015-06
Volume
33
Pages
33-41
ISSN
1075-9964 (ISSN-L)
DOI
10.1016/j.anaerobe.2015.01.005
OpenAlex
W1972550431
Cited by
55
References
83
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 7 · 2022: 8 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 11 · 2016: 1 · 2015: 3
FWCI
6.29
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Anaerobe (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
Takeda Pharmaceuticals, Inc (IISR Study 08-029LUB)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
chronic functional constipation, lubiprostone, gut microbiota, short-chain fatty acids, butyrate, archaea, breath methane, stool frequency, gut microbiota diversity, 16S rRNA gene
MeSH terms
Lubiprostone, Gastrointestinal Microbiome, Adult, Aged, Chronic Disease, Constipation, Fatty Acids, Volatile, Female, Humans, Male, Middle Aged, RNA, Ribosomal, 16S, Case-Control Studies, Treatment Outcome, Gene Dosage, Biodiversity, Metagenome, Chloride Channel Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review